Literature DB >> 27394166

Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Karima Ait-Aissa1, Johnathan D Ebben2, Andrew O Kadlec1, Andreas M Beyer3.   

Abstract

Aging, cancer, and chronic disease have remained at the forefront of basic biological research for decades. Within this context, significant attention has been paid to the role of telomerase, the enzyme responsible for lengthening telomeres, the nucleotide sequences located at the end of chromosomes found in the nucleus. Alterations in telomere length and telomerase activity are a common denominator to the underlying pathology of these diseases. While nuclear-specific, telomere-lengthening effects of telomerase impact cellular/organismal aging and cancer development, non-canonical, extra-nuclear, and non-telomere-lengthening contributions of telomerase have only recently been described and their exact physiological implications are ill defined. Although the mechanism remains unclear, recent reports reveal that the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), regulates levels of mitochondrial-derived reactive oxygen species (mtROS), independent of its established role in the nucleus. Telomerase inhibition has been the target of chemotherapy (directed or indirectly) for over a decade now, yet no telomerase inhibitor is FDA approved and few are currently in late-stage clinical trials, possibly due to underappreciation of the distinct extra-nuclear functions of telomerase. Moreover, evaluation of telomerase-specific therapies is largely limited to the context of chemotherapy, despite reports of the beneficial effects of telomerase activation in the cardiovascular system in relation to such processes as endothelial dysfunction and myocardial infarction. Thus, there is a need for better understanding of telomerase-focused cell and organism physiology, as well as development of telomerase-specific therapies in relation to cancer and extension of these therapies to cardiovascular pathologies. This review will detail findings related to telomerase and evaluate its potential to serve as a therapeutic target.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aging; Cancer; Cardiovascular disease; Reactive oxygen species; Telomerase

Mesh:

Substances:

Year:  2016        PMID: 27394166      PMCID: PMC5026584          DOI: 10.1016/j.phrs.2016.07.003

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  106 in total

1.  p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis.

Authors:  L Chin; S E Artandi; Q Shen; A Tam; S L Lee; G J Gottlieb; C W Greider; R A DePinho
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

2.  Global expression profile of telomerase-associated genes in HeLa cells.

Authors:  Akhil Varshney; Suresh K Ramakrishnan; Amod Sharma; Baby Santosh; Jyoti Bala; Pramod K Yadava; Rishi Kumar Jaiswal
Journal:  Gene       Date:  2014-06-11       Impact factor: 3.688

Review 3.  Free radicals and antioxidants in human health: current status and future prospects.

Authors:  T P A Devasagayam; J C Tilak; K K Boloor; Ketaki S Sane; Saroj S Ghaskadbi; R D Lele
Journal:  J Assoc Physicians India       Date:  2004-10

4.  Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction.

Authors:  Tohru Minamino; Hideaki Miyauchi; Toshihiko Yoshida; Yasuo Ishida; Hideo Yoshida; Issei Komuro
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

Review 5.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

6.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

7.  Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects.

Authors:  Athanase Benetos; Jeffrey P Gardner; Mahmoud Zureik; Carlos Labat; Lu Xiaobin; Chris Adamopoulos; Mohamed Temmar; Kathryn E Bean; Frédérique Thomas; Abraham Aviv
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

8.  Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Serkalem Demissie; Masayuki Kimura; L Adrienne Cupples; Nader Rifai; Charles White; Thomas J Wang; Jeffrey P Gardner; Xiaogian Cao; Emelia J Benjamin; Daniel Levy; Abraham Aviv
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

9.  Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

Authors:  Michael A James; Weidong Wen; Yian Wang; Lauren A Byers; John V Heymach; Kevin R Coombes; Luc Girard; John Minna; Ming You
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response.

Authors:  Rozalyn M Anderson; Jamie L Barger; Michael G Edwards; Kristina H Braun; Clare E O'Connor; Tomas A Prolla; Richard Weindruch
Journal:  Aging Cell       Date:  2007-11-21       Impact factor: 9.304

View more
  8 in total

1.  Telomerase: Location, Location, Location?

Authors:  Andreas M Beyer; Laura E Norwood Toro
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-06       Impact factor: 8.311

2.  Telomerase reverse transcriptase protects against angiotensin II-induced microvascular endothelial dysfunction.

Authors:  Karima Ait-Aissa; Andrew O Kadlec; Joseph Hockenberry; David D Gutterman; Andreas M Beyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 5.125

Review 3.  Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.

Authors:  Nabeel Quryshi; Laura E Norwood Toro; Karima Ait-Aissa; Amanda Kong; Andreas M Beyer
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

4.  Telomerase Mediates Lymphocyte Proliferation but Not the Atherosclerosis-Suppressive Potential of Regulatory T-Cells.

Authors:  Gavin David Richardson; Andrew Sage; Karim Bennaceur; Nayef Al Zhrany; Jose Coelho-Lima; Emily Dookun; Lilia Draganova; Gabriele Saretzki; David T Breault; Ziad Mallat; Ioakim Spyridopoulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

5.  Independent and Combined Effects of Telomere Shortening and mtDNA4977 Deletion on Long-term Outcomes of Patients with Coronary Artery Disease.

Authors:  Cecilia Vecoli; Andrea Borghini; Silvia Pulignani; Antonella Mercuri; Stefano Turchi; Eugenio Picano; Maria Grazia Andreassi
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

6.  Telomerase therapy attenuates cardiotoxic effects of doxorubicin.

Authors:  Shambhabi Chatterjee; Teresa Hofer; Alessia Costa; Dongchao Lu; Sandor Batkai; Shashi Kumar Gupta; Emiliano Bolesani; Robert Zweigerdt; Diego Megias; Katrin Streckfuss-Bömeke; Christina Brandenberger; Thomas Thum; Christian Bär
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

7.  Camptothecin shows better promise than Curcumin in the inhibition of the Human Telomerase: A computational study.

Authors:  Adekunle Babajide Rowaiye; Yoroshi Joana Teca Mendes; Samson Ayodeji Olofinsae; John Breakthrough Oche; Oluwakemi Hannah Oladipo; Okiemute Ajiroghene Okpalefe; Joyce Oloaigbe Ogidigo
Journal:  Heliyon       Date:  2021-08-10

Review 8.  Telomeres and Telomerase in Heart Ontogenesis, Aging and Regeneration.

Authors:  Denis Nalobin; Svetlana Alipkina; Anna Gaidamaka; Alexander Glukhov; Zaza Khuchua
Journal:  Cells       Date:  2020-02-22       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.